Sunshine Act data collection delayed to January 2013, says USA's CMS

8 May 2012

In a web site posting last week, The US Center for Medicare and Medicaid Services (CSM) announced that manufacturers will not be required to collect data under the physician payment Sunshine provisions of the Patient Protection and Affordable Care Act before next January.

The CMS said it is “committed to addressing the valuable input received during the comment period, and to ensuring the accuracy of the data collected. In order to provide time for organizations to prepare for data submission and to sufficiently address the important input we received during the rulemaking process, CMS will not require data collection by applicable manufacturers and applicable group purchasing organizations before January 1, 2013.”

The Sunshine provisions, developed by US Senators Chuck Grassley (Republican, Iowa) and Herb Kohl (Democrat, Wisconsin), among other things, require manufacturers of drugs, devices, biologicals, and medical supplies that are covered under Medicare, Medicaid, or the Children’s Health Insurance Program (CHIP) to report annually to the CMS certain payments or other transfers of value to physicians and teaching hospitals. Although the statute requires the first report to be submitted by March 31, 2013 for payments made in calendar year 2012, the CMS has long exceeded its statutory deadline of October 1, 2011 for issuing implementing procedures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology